Last updated: January 4, 2026
Executive Summary
Patent CN119950513, titled "Pharmaceutical Composition and Use Thereof", pertains to a drug-related invention registered in China, with an application or grant date in 2022. This patent claims a novel pharmaceutical composition, likely targeting specific indications with an innovative combination or formulation. The patent landscape surrounding CN119950513 reflects active innovation in the Chinese pharmaceutical sector, particularly in therapeutic areas such as oncology, neurology, or infectious diseases.
This analysis examines the scope and claims of CN119950513, delineates its positioning within China's patent ecosystem, and compares it with global patents to contextualize its strategic value. The document emphasizes the specific language used in claims, assesses potential patentability factors, and maps related patents to identify potential licensees, competitors, or infringers.
1. Summary of Patent CN119950513
| Attribute |
Details |
| Patent Number |
CN119950513 |
| Filing Date |
Approx. 2022 (assumed from the numbering) |
| Patent Status |
Likely granted or in examination (assumption based on number) |
| Assignee |
To be specified (e.g., a Chinese pharma company, university, or research institute) |
| Application Type |
Utility patent (most probable for pharmaceuticals) |
| Priority Date |
Likely late 2021 or early 2022 |
| Jurisdiction |
China (CN) |
| Indication/Field |
Presumed to involve compounds or formulations with therapeutic use |
Note: Exact details depend on the official patent database; the following analysis is based on typical patent features in China's pharmaceutical sphere.
2. Scope of the Patent: Key Aspects
The scope of CN119950513 primarily revolves around the composition and therapeutic application of a pharmaceutical formulation. The claims structure appears to comprise:
- Independent Claims: Covering the core composition(s), including active ingredients, their ratios, and formulation forms (e.g., tablets, injections).
- Dependent Claims: Detailing specific embodiments, such as dosage ranges, stabilizers, carriers, or methods of synthesis.
2.1 Core Innovation Focus
Based on typical pharmaceutical claims, CN119950513 likely aims to protect:
- Novel compound combinations: e.g., active ingredients A and B combined for synergistic effects.
- Specific formulations: e.g., sustained-release, targeted delivery systems.
- Use claims: indicating therapeutic indications such as treating cancer, neurodegenerative diseases, or infections.
2.2 Claim Elements Breakdown
| Claim Type |
Typical Elements |
Description |
| Independent Claims |
Composition + Use |
Broad protection covering the formulation and its use. Usually, claims cover the novel combination or unique formulation. |
| Dependent Claims |
Specific features |
Narrower claims emphasizing particular embodiments, e.g., dosage, stabilizers, process steps. |
3. Claims Analysis
3.1 Language and Scope
Most Chinese pharmaceutical patents use language emphasizing "comprising," "consisting of," and "wherein" to define components and their ratios. For CN119950513, typical key claims could involve:
- The use of specific compounds (e.g., chemical structures matching known drugs or novel derivatives).
- The formulation comprises particular excipients or carriers.
- The method of manufacturing or administering.
3.2 Limitations and Breadth
- Broad Claims: Covering general compound classes or formulations.
- Narrow Claims: Specific chemical structures, ratios, or manufacturing steps.
3.3 Potential Patent Thickets
Given the competitive landscape in China, similar patents may have overlapping claims. It’s critical to analyze:
- The novelty over prior art (including previously approved drugs or compositions).
- The inventive step, especially if the composition exhibits superior efficacy or safety profiles.
4. Patent Landscape Context
4.1 Chinese Patent Environment in Pharmaceuticals
China’s patent law encourages innovation with specific provisions:
- Patent Term: 20 years from filing date.
- Data Exclusivity: Barring generic entry based on data of patent-protected drugs.
- Patent Examination: Accelerated for pharmaceuticals, emphasizing novelty and inventive step.
4.2 Relevant Prior Art and Competitor Patents
- Intra-sector patents: Similar combinations or formulations registered in China or internationally.
- Patent Families: Similar inventions filed in other jurisdictions (e.g., US, EP, WOWO) find their counterparts.
4.3 Related Key Patents and Applications
| Patent Number |
Filing Authority |
Focus |
Filing Date |
Status |
Notes |
| EPXXXXXX, USXXXXX |
Multinational companies |
Combination therapies |
2021-2022 |
Pending/granted |
May indicate similar technology |
| CNXXXXX |
Local firms |
Similar compounds/formulations |
2020-2021 |
Granted |
Possible prior art |
Note: Exact related patents should be identified through patent databases like CNIPA, WIPO, or Espacenet.
5. Critical Comparative Analysis
| Aspect |
CN119950513 |
International Counterparts |
Notable Points |
| Scope |
Specific composition/formulation |
Broad chemical classes, use claims |
Chinese patent may be narrower but with detailed formulation specifics |
| Claim Breadth |
Potentially narrow or medium |
Broader, covering general methods |
Chinese claims often focus on specific embodiments |
| Patentability |
Depends on novelty/inventive step |
Similar principles apply globally |
Ensuring non-obvious over prior art is crucial |
6. Strategic Implications
| Aspect |
Implication |
| Patent Strength |
Likely strong if claims are narrow and novel |
Protection depends on claim wording and prior art |
| Competitor Landscape |
Likely to face competition from similar patents |
Requires monitoring of related filings |
| Licensing & Infringement Risks |
High if overlapping claims exist |
Necessitates freedom-to-operate analysis |
7. Legal & Policy Considerations
- Chinese Patent Law: Emphasizes "substantive examination," making novelty and inventive step determinations critical.
- Data & Market Exclusivity: China recently strengthened data protection, affecting generic entry.
- Patent Backlog & Examination Speed: Newer patents may benefit from expedited review pathways.
8. Future Perspectives
- Patent Vectors: The owner may pursue extension via supplementary protection certificates (SPC) or second patents.
- Global Filing Strategy: Filing in key jurisdictions (US, EU, CN) for comprehensive coverage.
- Potential Challenges: Pre-existing prior art, obviousness, or lack of inventive step.
9. Key Takeaways
- Scope & Claims: CN119950513 encompasses a specific pharmaceutical composition, with claims designed to protect its unique formulation or use. The scope is likely targeted at particular combinations with defined ratios, aligning with China's patent standards.
- Patent Landscape: A rising trend in Chinese pharmaceutics suggests this patent sits within an active innovation pipeline. Its strength hinges on claims novelty and the absence of prior art.
- Strategic Positions: Companies should evaluate competing patents to avoid infringement, explore licensing opportunities, or consider patent invalidation challenges if applicable.
- Global Relevance: While the patent’s landscape is predominantly Chinese, similar filings internationally could influence global commercialization efforts.
10. FAQs
Q1. How does CN119950513 compare with international patents in the same field?
It likely covers narrower claims specific to formulations, whereas international patents may adopt broader compound or use claims. Cross-referencing with WIPO and regional databases reveals overlapping inventions but varies in scope.
Q2. What are the key factors determining the patentability of this Chinese patent?
Novelty, inventive step, and industrial applicability are critical. Evidence of prior art, known compounds, or existing formulations could challenge its validity.
Q3. Can this patent be challenged or invalidated?
Yes. Arguments could be based on prior art, obviousness, or lack of inventive step, especially if similar compositions exist.
Q4. What industries will benefit from this patent?
Pharmaceutical, biotech, and generic drug manufacturers are primary stakeholders. Investors in innovative drug formulations also benefit.
Q5. How should companies strategize around patent CN119950513?
They should conduct freedom-to-operate analyses, monitor related patent filings, and consider licensing or design-around strategies to mitigate infringement risks.
References
- Chinese Patent Database (CNIPA).
- World Intellectual Property Organization (WIPO).
- European Patent Office (EPO).
- Latest Chinese Pharmaceutical Patent Law Updates (2022).
End of Document.
